Clinical trials: Solid Tumor, Adult
Advanced Solid Malignancies
Study of AZD9150 and MEDI4736 (Durvalumab) in Japanese Adult Patients With Advanced Solid Malignancies
This is a phase I, open-label study to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of AZD9150 monotherapy and AZD9150 in combination with durvalumab in Japanese patients with advanced…
- Trial name
- NCT03394144
- Testing
- AZD9150, Durvalumab
- Where
- 2 sites in Japan
- Volunteers
- 11 people
- Sponsor
- AstraZeneca
Breast Cancer, Cholangiocarcinoma
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor an NTRK1/2/3, ROS1, or ALK gene fusion.
- Conditions
- Breast Cancer, Cholangiocarcinoma, Colorectal Cancer, Head and Neck Neoplasms
- Trial name
- STARTRK-2 (NCT02568267)
- Testing
- Entrectinib
- Where
- 120 sites in United States, Australia and 14 more
- Volunteers
- 534 people
- Sponsor
- Hoffmann-La Roche
Solid Tumor, Adult
A Study of HMPL-453 in Patients With Advanced Solid Malignancies
This is a dose escalation study consisting of two stages: Dose-escalation stage (stage 1): Patients will take a single dose of HMPL-453 on Day 1 and will be followed for one week for safety observations.
- Trial name
- NCT03160833
- Testing
- HMPL-453
- Where
- 2 sites in China
- Volunteers
- 33 people
- Sponsor
- Hutchison Medipharma Limited
Solid Tumours
A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors
A phase 1/2a, open-label, first-in-human study mainly aimed to evaluate the safety and tolerability of BMS-986517 in participants with solid tumors
- Trial name
- NCT07160725
- Testing
- BMS-986517, Pumitamig
- Where
- 20 sites in United States, China and 3 more
- Volunteers
- 540 people
- Sponsor
- Bristol-Myers Squibb
Solid Tumors With FGFR2 Alterations, Adult
A Study of 3HP-2827 in Treatment of Unresectable or Metastatic Solid Tumors With FGFR2 Alterations
The study is being conducted to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of 3HP-2827 in the treatment of unresectable or metastatic solid tumors with FGFR2 alterations.
- Trial name
- NCT06378593
- Testing
- 3HP-2827
- Where
- 2 sites in China
- Volunteers
- 130 people
- Sponsor
- 3H (Suzhou) Pharmaceuticals Co., Ltd.
Non-small Cell Lung Cancer, Colorectal Cancer
A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China
This is a Phase 1, open-label dose-escalation study to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) and assess the DLT of JAB-3312.
- Conditions
- Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Carcinoma, Esophageal Squamous Cell Carcinoma
- Trial name
- NCT04121286
- Testing
- JAB-3312
- Where
- 5 sites in China
- Volunteers
- 17 people
- Sponsor
- Allist Pharmaceuticals, Inc.
Advanced or Metastatic Solid Tumors
Study of NMS-1286937 in Adult Patients With Advanced/Metastatic Solid Tumors
The purpose of this study is to evaluate the safety and tolerability of NMS-1286937, a polo-like-kinase 1 inhibitor, in patients with advanced metastatic solid tumor.
- Trial name
- NCT01014429
- Testing
- NMS-1286937
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Nerviano Medical Sciences
Solid Tumors, Hepatic Impairment
Pharmacokinetics (PK) of TKI258 in Cancer Patients With Normal and Impaired Hepatic Function
This is a multi-center, open label study to assess pharmacokinetics (PK) of TKI258 at single-dose and steady state in adult cancer patients either with mild, moderate or severe hepatic impairment or with normal hepatic function.
- Trial name
- NCT01443481
- Testing
- Dovitinib
- Where
- 12 sites in United States, Belgium and 4 more
- Volunteers
- 38 people
- Sponsor
- Novartis Pharmaceuticals
RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer
A Study of TY-1091 in Patients With Advanced Solid Tumors
This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antineoplastic activity of TY-1091 administered orally in…
- Conditions
- RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET-altered Papillary Thyroid Cancer, Neoplasms
- Trial name
- NCT05675605
- Testing
- TY-1091
- Where
- China
- Volunteers
- 248 people
- Sponsor
- TYK Medicines, Inc
Neoplasm Malignant
Effect of SAR302503 on ECG Activity in Patients With Solid Tumors
Primary Objective: To assess the effect of SAR302503 (500 mg) administered as 14-day repeated doses on the QTcF interval compared to 1-day placebo in patients with advanced solid tumors.
- Trial name
- NCT01836705
- Testing
- SAR302503 (TG101348), Panolosetron
- Where
- 10 sites in United States, Belgium
- Volunteers
- 60 people
- Sponsor
- Bristol-Myers Squibb
Solid Tumor, Adult
A Phase 1 Study of ADA-011 for Subjects With Advanced Solid Tumors
This study consists of dose escalation evaluation to determine the safety and tolerability of ADA-011 as a monotherapy. Following dose escalation, one or more dose expansion cohorts in selected indications will be explored to…
- Trial name
- NCT05601219
- Testing
- ADA-011, PD(L)-1 inhibitor
- Where
- 5 sites in United States
- Volunteers
- 46 people
- Sponsor
- Adanate, Inc
NSCLC, Solid Tumor
A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China
To assess safety, tolerability, PK, efficacy and determine recommended phase 2 dose (RP2D) of JAB-21822 (glecirasib) administered in adult participants with KRAS p.G12C-mutant advanced solid tumors.
- Trial name
- NCT05009329
- Testing
- JAB-21822
- Where
- China
- Volunteers
- 315 people
- Sponsor
- Allist Pharmaceuticals, Inc.
Cancer
Dose Escalation Safety Study of TL32711 in Adults With Refractory Solid Tumors or Lymphoma
A Phase 1 open-label, non-randomized dose escalation study to determine the maximum tolerated dose (MTD) and characterize the safety and tolerability of Birinapant (TL32711).
- Trial name
- NCT00993239
- Testing
- Birinapant (TL32711)
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- TetraLogic Pharmaceuticals
Advanced Malignant Solid Tumors
A Dose Escalation Study of MLN7243 (TAK-243) in Adult Participants With Advanced Solid Tumors
The purpose of this study is to evaluate safety and tolerability (establish maximum tolerated dose [MTD], inform the recommended phase 2 dose [RP2D], and identify the dose-limiting toxicities [DLTs]) of MLN7243.
- Trial name
- NCT02045095
- Testing
- MLN7243
- Where
- 7 sites in United States
- Volunteers
- 29 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Advanced Solid Tumor
Study of PM54 in Combination With Cytotoxic and Targeted Agents in Adult Participants With Advanced Malignancies
The primary purpose of this study is to evaluate the safety, tolerability and recommended dose (RD) of PM54 in combination with cytotoxic and targeted anticancer agents in adult participants with advanced solid tumors.
- Trial name
- NCT07839819
- Testing
- PM54, Irinotecan, Doxorubicin
- Where
- 9 sites in United States, France and 2 more
- Volunteers
- 231 people
- Sponsor
- PharmaMar
Adult Solid Tumor
Study of RP-6306 With Gemcitabine in Advanced Solid Tumors
The primary purpose of this study is to assess the safety and tolerability of RP-6306 in combination gemcitabine, in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD) of RP-6306 in…
- Trial name
- NCT05147272
- Testing
- RP-6306 (oral PKMYT1 inhibitor)
- Where
- 11 sites in United States, Canada and 1 more
- Volunteers
- 67 people
- Sponsor
- Debiopharm International SA
Advanced Solid Tumors, Triple Negative Breast Cancer
Safety of TT-00420 (Tinengotinib) Monotherapy in Patients With Advanced Solid Tumors and Triple Negative Breast Cancer
This is a first-in-human, phase I clinical research study with TT-00420, an investigational, oral, multi-target, dual mechanism kinase inhibitor targeting both mitosis and tumor micro-environment, for the treatment of triple…
- Trial name
- NCT03654547
- Testing
- TT-00420
- Where
- 2 sites in United States, China
- Volunteers
- 48 people
- Sponsor
- TransThera Sciences (Nanjing), Inc.
Cancer, Pancreatic Cancer
9-ING-41 in Patients With Advanced Cancers
GSK-3β is a potentially important therapeutic target in human malignancies. The Actuate 1801 Phase 1/2 study is designed to evaluate the safety and efficacy of 9-ING-41, a potent GSK-3β inhibitor, as a single agent and in…
- Conditions
- Cancer, Pancreatic Cancer, Sarcoma, Renal Cancer
- Trial name
- NCT03678883
- Testing
- 9-ING-41, Gemcitabine - 21 day cycle, Doxorubicin.
- Where
- 66 sites in United States, Belgium and 5 more
- Volunteers
- 350 people
- Sponsor
- Actuate Therapeutics Inc.
Unspecified Adult Solid Tumor, Protocol Specific
GPX-100 in Treating Patients With Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of GPX-100 in treating patients who have solid tumors.
- Trial name
- NCT00003403
- Testing
- GPX-100
- Where
- 2 sites in United States
- Sponsor
- Gem Pharmaceuticals
Tumors
First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Mirvetuximab Soravtansine in Adults With Ovarian Cancer and Other Folate Receptor 1 (FOLR1)-Positive Solid Tumors
The purpose of this study is to test mirvetuximab soravtansine (IMGN853) in participants with ovarian cancer and other FOLR-1 positive tumors.
- Trial name
- IMGN853-0401 (NCT01609556)
- Testing
- Mirvetuximab soravtansine
- Where
- 12 sites in United States, Canada
- Volunteers
- 206 people
- Sponsor
- ImmunoGen, Inc.